SCHEMBL4036457

SCHEMBL4036457

O=C(NC1CCOCC1)C(C1CCCCC1)C1(c2ccc(Cl)cc2)Nc2cc(F)c(Cl)cc2N1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 6/20 0.43
KCNH2 Q12809 4/20 0.43
CYP3A4 P08684 3/20 0.43
CYP2D6 P10635 2/20 0.38
CYP2C9 P11712 2/20 0.38
RAB9A P51151 2/20 0.37
NPC1 O15118 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
IDO1 P14902 1/20 0.37
P2RX7 Q99572 1/20 0.36
FPR2 P25090 1/20 0.36
KDM1A O60341 1/20 0.36
MET P08581 1/20 0.35
P2RX3 P56373 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
MEN1 O00255 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KMT2A Q03164 1/20 0.34
EPHX1 P07099 1/20 0.34
LMNA P02545 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4039331 0.97 NR1H4 (0.44) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4038118 0.97 NR1H4 (0.44) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4037198 0.95 NR1H4 (0.42) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4038655 0.93 KCNH2 (0.48) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4036376 0.93 KCNH2 (0.48) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4034374 0.93 KCNH2 (0.48) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4039537 0.93 KCNH2 (0.48) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4036578 0.93 KCNH2 (0.48) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4040768 0.92 NR1H4 (0.43) NR1H4KCNH2CYP3A4CYP2D6CYP2C9
SCHEMBL4038576 0.92 NR1H4 (0.43) NR1H4KCNH2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3043865-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2016-07-20 EP disclosed
WO-2015036442-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2015-03-19 WO disclosed
EP-2038259-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F.HOFFMANN-LA ROCHE AG (CH) 2009-03-25 EP disclosed
WO-2008000643-A1 BENZIMIDAZOLE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, THEIR USE AS FXR AGONISTS AND PHARMACEUTICAL PREPARATIONS CONTAINING THE SAME F. HOFFMANN-LA ROCHE AG (CH) 2008-01-03 WO disclosed